Browse FHL1

Summary
SymbolFHL1
Namefour and a half LIM domains 1
Aliases SLIM1; KYO-T; bA535K18.1; FHL1B; XMPMA; FLH1A; MGC111107; Four-and-a-half LIM domains 1; LIM protein SLIMMER ......
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cytoplasm.; SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Nucleus.; SUBCELLULAR LOCATION: Isoform 2: Nucleus. Cytoplasm, cytosol. Note=Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes.
Domain PF00412 LIM domain
Function

May have an involvement in muscle development or hypertrophy.

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0000086 G2/M transition of mitotic cell cycle
GO:0001558 regulation of cell growth
GO:0003254 regulation of membrane depolarization
GO:0006813 potassium ion transport
GO:0007346 regulation of mitotic cell cycle
GO:0007517 muscle organ development
GO:0010389 regulation of G2/M transition of mitotic cell cycle
GO:0010948 negative regulation of cell cycle process
GO:0010959 regulation of metal ion transport
GO:0010972 negative regulation of G2/M transition of mitotic cell cycle
GO:0015672 monovalent inorganic cation transport
GO:0016049 cell growth
GO:0022898 regulation of transmembrane transporter activity
GO:0030308 negative regulation of cell growth
GO:0032409 regulation of transporter activity
GO:0032412 regulation of ion transmembrane transporter activity
GO:0032844 regulation of homeostatic process
GO:0034762 regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0042391 regulation of membrane potential
GO:0043266 regulation of potassium ion transport
GO:0043268 positive regulation of potassium ion transport
GO:0043270 positive regulation of ion transport
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044839 cell cycle G2/M phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045786 negative regulation of cell cycle
GO:0045926 negative regulation of growth
GO:0045930 negative regulation of mitotic cell cycle
GO:0051899 membrane depolarization
GO:0071804 cellular potassium ion transport
GO:0071805 potassium ion transmembrane transport
GO:1901016 regulation of potassium ion transmembrane transporter activity
GO:1901379 regulation of potassium ion transmembrane transport
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902749 regulation of cell cycle G2/M phase transition
GO:1902750 negative regulation of cell cycle G2/M phase transition
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1904062 regulation of cation transmembrane transport
GO:2000021 regulation of ion homeostasis
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
Molecular Function GO:0044325 ion channel binding
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
> KEGG and Reactome Pathway
 
KEGG hsa04630 Jak-STAT signaling pathway
Reactome -
Summary
SymbolFHL1
Namefour and a half LIM domains 1
Aliases SLIM1; KYO-T; bA535K18.1; FHL1B; XMPMA; FLH1A; MGC111107; Four-and-a-half LIM domains 1; LIM protein SLIMMER ......
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FHL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolFHL1
Namefour and a half LIM domains 1
Aliases SLIM1; KYO-T; bA535K18.1; FHL1B; XMPMA; FLH1A; MGC111107; Four-and-a-half LIM domains 1; LIM protein SLIMMER ......
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FHL1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFHL1
Namefour and a half LIM domains 1
Aliases SLIM1; KYO-T; bA535K18.1; FHL1B; XMPMA; FLH1A; MGC111107; Four-and-a-half LIM domains 1; LIM protein SLIMMER ......
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FHL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.290.0107
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.420.231
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4460.722
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2170.827
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1840.937
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2580.93
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2210.648
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6370.706
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1050.951
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1120.626
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5140.647
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4790.026
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FHL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFHL1
Namefour and a half LIM domains 1
Aliases SLIM1; KYO-T; bA535K18.1; FHL1B; XMPMA; FLH1A; MGC111107; Four-and-a-half LIM domains 1; LIM protein SLIMMER ......
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FHL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFHL1
Namefour and a half LIM domains 1
Aliases SLIM1; KYO-T; bA535K18.1; FHL1B; XMPMA; FLH1A; MGC111107; Four-and-a-half LIM domains 1; LIM protein SLIMMER ......
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FHL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FHL1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFHL1
Namefour and a half LIM domains 1
Aliases SLIM1; KYO-T; bA535K18.1; FHL1B; XMPMA; FLH1A; MGC111107; Four-and-a-half LIM domains 1; LIM protein SLIMMER ......
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FHL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFHL1
Namefour and a half LIM domains 1
Aliases SLIM1; KYO-T; bA535K18.1; FHL1B; XMPMA; FLH1A; MGC111107; Four-and-a-half LIM domains 1; LIM protein SLIMMER ......
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FHL1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFHL1
Namefour and a half LIM domains 1
Aliases SLIM1; KYO-T; bA535K18.1; FHL1B; XMPMA; FLH1A; MGC111107; Four-and-a-half LIM domains 1; LIM protein SLIMMER ......
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FHL1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFHL1
Namefour and a half LIM domains 1
Aliases SLIM1; KYO-T; bA535K18.1; FHL1B; XMPMA; FLH1A; MGC111107; Four-and-a-half LIM domains 1; LIM protein SLIMMER ......
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FHL1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.